Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2014-07-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1406123111PMID 25071175PMCID PMC4136575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2016cited by this paper
• Evolutionary dynamics of cancer in response to targeted combination therapy

  2013cited by this paper
• β-Catenin induces T-cell transformation by promoting genomic instability

  2013influential reference
• β-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL.

  2013cited by this paper
• Converting cancer therapies into cures: lessons from infectious diseases.

  2012influential reference
• Wnt/β-catenin signaling and disease.

  2012cited by this paper
• b-Catenin-Driven Cancers Require a YAP 1 Transcriptional Complex for Survival and Tumorigenesis

  2012influential reference
• Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin

  2011cited by this paper
• Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

  2011cited by this paper
• Lentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• A general chemical method to regulate protein stability in the mammalian central nervous system.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

  2010cited by this paper
• Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation.

  2007cited by this paper
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

  2007influential reference
• Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch

  2006cited by this paper
• A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

  2006cited by this paper
• Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor

  2006cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005influential reference
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Stabilized β-Catenin Extends Thymocyte Survival by Up-Regulating Bcl-xL

  2005cited by this paper
• A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors

  2005cited by this paper
• Stabilized beta-catenin extends thymocyte survival by up-regulating Bcl-xL.

  2005influential reference
• KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Splice mutations in the p53 gene: case report and review of the literature

  2003cited by this paper
• Wnt/β-Catenin/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of the Signaling Pathway

  2002cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas.

  2001cited by this paper
• Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer.

  2001cited by this paper
• Wnt signaling and cancer.

  2000influential reference
• Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein.

  2000influential reference
• A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS

  2000cited by this paper
• Inhibition of Wnt signaling by ICAT, a novel β-catenin-interacting protein

  2000cited by this paper
• Reversible tumorigenesis by MYC in hematopoietic lineages.

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

  1999cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.

  1998cited by this paper
• Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations.

  1998cited by this paper
• Identification of c-MYC as a target of the APC pathway.

  1998cited by this paper
• A BRCA1 nonsense mutation causes exon skipping.

  1998cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

  1997cited by this paper
• Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.

  1990cited by this paper
• Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

  1990cited by this paper

• Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies

  2023cites this paper
• Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma

  2022cites this paper
• Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research

  2022cites this paper
• Models of Cancer Drug Discovery and Response to Therapy

  2021cites this paper
• miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells.

  2021cites this paper
• Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression

  2020cites this paper
• Targeting acquired oncogenic burden in resilient pancreatic cancer: a novel benefit from marine polyphenols

  2019cites this paper
• Resisting Resistance

  2019cites this paper
• BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML

  2018cites this paper
• PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression

  2018cites this paper
• Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

  2017cites this paper
• Oncogene addiction in chronic myeloid leukaemia

  2017cites this paper
• β-catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl

  2016cites this paper
• A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma

  2015cites this paper